<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">inovmed</journal-id><journal-title-group><journal-title xml:lang="ru">Инновационная медицина Кубани</journal-title><trans-title-group xml:lang="en"><trans-title>Innovative Medicine of Kuban</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2541-9897</issn><publisher><publisher-name>Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35401/2500-0268-2019-14-2-51-57</article-id><article-id custom-type="elpub" pub-id-type="custom">inovmed-196</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Дислипидемия у реципиентов почки</article-title><trans-title-group xml:lang="en"><trans-title>Dyslipidemia in kidney receiver</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6515-6319</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мартиросян</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Martirosyan</surname><given-names>S. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мартиросян Соня Макичевна – врач-кардиолог кардиологического отделения</p><p>344011, Ростов-на-Дону, пер. Днепровский, 122/1</p></bio><bio xml:lang="en"><p>Martirosyan Sonia M. – cardiologist of the cardiology department</p><p>344011, Rostov-on-Don, 122.1, Dneрrovsky lane.</p></bio><email xlink:type="simple">md.martirosyan.krd@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8600-0199</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Космачева</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosmacheva</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Космачева Елена Дмитриевна – доктор медицинских наук, заместитель главного врача по лечебной работе, НИИ – ККБ № 1, заведующая кафедрой терапии № 1 ФПК и ППС, КубГМУ</p></bio><bio xml:lang="en"><p>Kosmacheva Elena D. – Dr. of Sci. (Med.), Chief Medical Officer, Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1, Head of Department of Therapy no. 1 ATF, Kuban State Medical University</p></bio><email xlink:type="simple">Kosmachova_h@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Клинико-диагностический центр «Здоровье»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Clinical and Diagnostic Center «Zdorovie»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского Министерства здравоохранения Краснодарского края; Кубанский государственный медицинский университет Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Research Institute – Ochapovsky Regional Clinical Hospital #1; Kuban State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2019</year></pub-date><volume>0</volume><issue>2</issue><fpage>51</fpage><lpage>57</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мартиросян С.М., Космачева Е.Д., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Мартиросян С.М., Космачева Е.Д.</copyright-holder><copyright-holder xml:lang="en">Martirosyan S.M., Kosmacheva E.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.innovmedkub.ru/jour/article/view/196">https://www.innovmedkub.ru/jour/article/view/196</self-uri><abstract><sec><title>Введение</title><p>Введение. Трансплантация почки является «золотым стандартом» в лечении пациентов с терминальной почечной недостаточностью. Тем не менее основными причинами гибели реципиентов, потери ренального аллотрансплантата являются сердечно-сосудистые заболевания, а одним из наиболее значимых факторов риска и прогрессирования сердечно-сосудистой патологии остается нарушение липидного обмена.</p></sec><sec><title>Цель</title><p>Цель. Оценить динамику дислипидемии до и в различные сроки после трансплантации почки и выявить взаимосвязь нарушения метаболизма липидов с функционированием ренального трансплантата.</p></sec><sec><title>Материал и методы</title><p>Материал и методы.Проведено ретроспективное обсервационное когортное исследование в единой группе наблюдения динамики липидного спектра в сроки до трансплантации почки и через 6, 12 и 36 месяцев двухсот реципиентов печени в возрасте 40,18 ± 10,33 лет, среди них женщин – 41,5%, мужчин – 58,5%. Статистический анализ проводили с помощью программы STATISTICA 10.0. Критический уровень значимости при проверке статистических гипотез в данном исследовании принимался равным 0,05. Для поиска факторов, ассоциированных с дислипидемией, применялся метод мультифакторной логистической регрессии. </p></sec><sec><title>Результаты</title><p>Результаты. Уровень общего холестерина до трансплантации составил 4,34 ± 1,21 ммоль/л, в сравнении с исходным показателем общего  холестерина увеличение в динамике через 12 и 36 месяцев составило 17,5% (р = 0,02), 22,9% (р = 0,03) соответственно.  Уровень липопротеидов низкой плотности (ЛПНП) в изученной когорте реципиентов – до 2,36 ± 1,21 ммоль, через 6 месяцев увеличился на 12,3% (р = 0,02), через год на 5,9% (р = 0,21) и спустя 36 месяцев отличался от исходного на 14,8% (р = 0,01). Через три года посттрансплантационного  периода липопротеиды  высокой плотности (ЛПВП) снизились на 12,3% (р = 0,01). В сравнении с исходным уровнем до трансплантации увеличились на 8,9% (р = 0,03) и 16,7% (р = 0,01) через 12 и 36 месяцев соответственно. Факторами, ассоциированными с дислипидемией,  являются: возраст – 1,21–1,7 (р &lt; 0,02), сахарный диабет – 1,1–1,5 (р &lt; 0,03), скорость клубочковой фильтрации (кг/ м2) – 1,23–1,32 (р &lt; 0,02), протеинурия (г/л) – 1,55–2,1 (р &lt; 0,001), индекс массы миокарда левого желудочка (кг/м2) – 1,23–1,55 (р &lt; 0,03), гемоглобин (г/л) – 1,1–1,23 (р &lt; 0,04), систолическое артериальное давление – 1,2–2,1 (р &lt; 0,001), диастолическое артериальное давление – 1,1–2,2 (р &lt; 0,002). Выявлена отрицательная корреляционная взаимосвязь между уровнем холестерина и выживаемостью ренального аллографта, оцененная по скорости клубочковой фильтрации (р = 0,003). Уровень общего холестерина оказался значимым независимым предиктором выживаемости и функционирования ренального аллотрансплантата через 3 года после трансплантации.</p></sec><sec><title>Заключение</title><p>Заключение. Выявлено прогрессирующее нарушение липидного спектра в отдаленном посттрансплантационном периоде, дислипидемия является значимым модицифируемым предиктором успешности трансплантации почки.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Kidney transplantation is the gold standard of treatment in patients with a terminal renal failure. Nevertheless, the main reason for death of recipients, loss of the renal allograft is cardiovascular disease, and disorder of lipid profile remains one of the most significant risk factors and progressing of cardiovascular pathology.</p></sec><sec><title>Aim</title><p>Aim. We estimated dyslipidemia dynamics before and at various terms after kidney transplantation and we tried to reveal interrelation of disorder of lipid metabolism with renal transplant functioning.</p></sec><sec><title>Material and methods</title><p>Material and methods.The retrospective observational research of the cohort in a uniform group of lipid profile dynamics observation in terms before kidney transplantation and in 6, 12 and 36 months of two hundred liver recipients at the age of 40.18 ± 10.33 years has been conducted. Among those there was 41.5% female patients and 58.5% male patients. The statistical analysis was carried out by means of STATISTICA 10.0 program. The critical significance value while checking statistical  hypotheses in this research was accepted equal 0.05. The method of multifactorial logistic regression was applied to search factors associated with a dyslipidemia. </p></sec><sec><title>Results</title><p>Results. Level of the general cholesterol before transplantation was 4.34 ± 1.21 mmol/l, in comparison with an initial indicator of the general cholesterol increase in dynamics in 12 and 36 months was 17.5% (р = 0.02), 22.9% (р = 0.03), respectively. The LDL level in the studied cohort of recipients was around 2.36 ± 1.21 mmol, and in 6 months it increased by 12.3% (р = 0.02), in a year for 5.9% (р = 0.21) and 36 months later differed from initial on 14.8 (р = 0.01). In three years after transplantation period LPVP decreased by 12.3% (р = 0.01). In comparison with initial level before transplantation  they increased on 8.9% (р = 0.03) и 16.7% (р = 0.01) in 12 and 36 months, respectively. The factors associated with dyslipidemia is the age – 1.21–1.7 (р &lt; 0.02), diabetes – 1.1–1.5 (р &lt; 0.03), the speed of glomerular filtration (kg/sq.m) – 1.23–1.32 (р &lt; 0.02), proteinuria (g/l) – 1.55–2.1 (р &lt; 0.001), the left ventricle myocardium mass index (kg/sq.m) – 1.23–1.55  (р &lt; 0.03), hemoglobin (g/l) – 1.1–1.23 (р &lt; 0.04), systolic arterial blood pressure – 1.2–2.1 (р &lt; 0.001), diastolic arterial blood pressure – 1.1–2.2 (р &lt; 0.002). The negative correlational interrelation between the level of cholesterol and survival of the renal allograft, estimated on the speed of glomerular filtration was revealed (р = 0.003). Level of the general cholesterol was a significant independent predictor for survival and functioning of the renal allotransplantat in 3 years after transplantation.</p></sec><sec><title>Conclusion</title><p>Conclusion. Тhe progressing disorder of a lipid profile in the long-term post-transplantation period was revealed, dyslipidemia is a significant modified predictor of successful kidney transplantation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>трансплантация почки</kwd><kwd>дислипидемия</kwd><kwd>хроническая болезнь почек</kwd></kwd-group><kwd-group xml:lang="en"><kwd>kidney transplantation</kwd><kwd>dyslipidemia</kwd><kwd>chronic renal disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kasiske BL, Israni AK, Snyder JJ, Skeans MA et al. A simple tool to predict outcomes after kidney transplant. Am. J. Kidney Dis. 2010;56(5):947-960.</mixed-citation><mixed-citation xml:lang="en">Kasiske  BL,  Israni AK,  Snyder  JJ, Skeans  MA et  al. A simple  tool  to  predict  outcomes  after  kidney transplant. Am. J. Kidney Dis. 2010;56(5):947-960.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am. J. of Kidney Dis. 2012;60(5):850-886.</mixed-citation><mixed-citation xml:lang="en">KDOQI Clinical Practice Guideline for Diabetes and   CKD:   2012   Update.   Am.   J.   of   Kidney   Dis. 2012;60(5):850-886.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">SRDS Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2014;63:295-306.</mixed-citation><mixed-citation xml:lang="en">SRDS  Annual  Data  Report.  Atlas  of  Chronic Kidney  Disease  and  End-Stage  Renal  Disease  in  the United States. 2014;63:295-306.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Catapano AL, Graham I, Backer G De, Wiklund O et al. ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058.</mixed-citation><mixed-citation xml:lang="en">Catapano AL, Graham I, Backer G De, Wiklund O et al. ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Parmar JA, Joshi AG, Chakrabarti M. Dyslipidemia and chronic kidney disease. ISRJ. 2014;3:396-397.</mixed-citation><mixed-citation xml:lang="en">Parmar JA, Joshi AG, Chakrabarti M. Dyslipidemia and chronic kidney disease. ISRJ. 2014;3:396-397.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Balode AA, Khan ZH. Serum lipid profile in chronic kidney disease patients on haemodialysis. IJAR. 2013;3:0-22.</mixed-citation><mixed-citation xml:lang="en">Balode  AA,  Khan  ZH.  Serum  lipid  profile  in chronic kidney disease patients on haemodialysis. IJAR. 2013;3:0-22.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mikolasevic I, Zutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35-45.</mixed-citation><mixed-citation xml:lang="en">Mikolasevic  I, Zutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35-45.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Piecha G, Adamczak M, Ritz E. Dyslipidemia in chronic kidney disease: pathogenesis and intervention. Pol Arch Med Wewn. 2009;119(7-8):487-92.</mixed-citation><mixed-citation xml:lang="en">Piecha G, Adamczak M, Ritz E. Dyslipidemia in chronic  kidney  disease:  pathogenesis  and  intervention. Pol Arch Med Wewn. 2009;119(7-8):487-92.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Herrington W, Emberson J, Staplin N, et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clinical journal of the American Society of Nephrology. 2014;9(5):914-9.</mixed-citation><mixed-citation xml:lang="en">Herrington W, Emberson J, Staplin N, et al. The effect  of lowering  LDL cholesterol  on vascular  access patency: post hoc analysis of the Study of Heart and Renal Protection.  Clinical  journal of the American Society of Nephrology. 2014;9(5):914-9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Polak WG, Jezior D, Garcarek J et al. Incidence and outcome of transplant renal artery stenosis: Single center experience. Transplant Proc. 2006;38:131-132.</mixed-citation><mixed-citation xml:lang="en">Polak WG, Jezior D, Garcarek J et al. Incidence and outcome  of transplant  renal artery stenosis:  Single center experience. Transplant Proc. 2006;38:131-132.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Мартиросян С., Космачева Е. Динамика факторов риска кардиоваскулярных осложнений у перенесших трансплантацию почки. Врач. 2018; 29(1):40-42.</mixed-citation><mixed-citation xml:lang="en">Martirosyan  S., Kosmacheva  Е. Dinamika  faktorov riska kardiovaskulyarnyh oslozhnenij u perenesshih transplantaciyu pochki. Vrach. 2018;29(1):40-42. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Мартиросян С.М., Космачева Е.Д. Гипертрофия миокарда левого желудочка как маркер артериальной гипертонии у реципиентов почки. В книге: Артериальная гипертония 2017 как междисциплинарная проблема. Сборник тезисов XIII Всероссийского конгресса. 2017, 19 с.</mixed-citation><mixed-citation xml:lang="en">Martirosyan S.M., Kosmacheva Е.D. Gipertrofiya  miokarda  levogo  zheludochka  kak marker arterial’noj gipertonii u recipientov pochki. V knige: Arterial’naya gipertoniya 2017 kak mezhdisciplinarnaya problema Sbornik tezisov XIII Vserossijskogo kongressa. 2017, 19 р. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kiyokazu Akioka, Sirou Takahara, Seiji Ichikawa, Norio Yoshimura, Takahiro Akiyama, Shinichi Ohshima Factors predicting long-term graft survival after kidney transplantation: multicenter study in Japan. World J. Surg. 2005;29 (2):249-56.</mixed-citation><mixed-citation xml:lang="en">Kiyokazu Akioka, Sirou Takahara, Seiji Ichikawa, Norio Yoshimura, Takahiro Akiyama, Shinichi Ohshima Factors predicting long-term graft survival after kidney transplantation:   multicenter   study  in  Japan.  World  J. Surg. 2005;29 (2):249-56.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Roodnat JJ, Mulder PGH. Proteinuria and death risk in renal transplant population. Transplant. Proc. 2001;33:1170-171.</mixed-citation><mixed-citation xml:lang="en">Roodnat JJ, Mulder PGH. Proteinuria and death risk  in  renal  transplant  population.  Transplant.  Proc. 2001;33:1170-171.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Araki M, Flechner SM, Ismail HR et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006;81:335-341.</mixed-citation><mixed-citation xml:lang="en">Araki M, Flechner SM, Ismail HR et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006;81:335-341.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Boots, J.M., Christiaans, M.H., van Hooff, J.P. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs. 2004;64:2047-2073.</mixed-citation><mixed-citation xml:lang="en">Boots,   J.M.,   Christiaans,   M.H.,   van   Hooff, J.P. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs. 2004;64:2047-2073.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jun H., Kim MG, Jung CW. Clinical advantages including medication adherence with conversion to oncedaily advagraf and sirolimus combination in stable kidney recipients. Int J Clin Pharmacol Ther. 2016;54(2):81-86.</mixed-citation><mixed-citation xml:lang="en">Jun H., Kim MG, Jung CW. Clinical advantages including medication adherence with conversion to oncedaily advagraf and sirolimus combination in stable kidney recipients. Int J Clin Pharmacol Ther. 2016;54(2):81-86.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Oberholzer J, Thielke J, Hatipoglu B et al. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. Transplant Proc. 2005;37:999-1000.</mixed-citation><mixed-citation xml:lang="en">Oberholzer J, Thielke J, Hatipoglu B et al. Immediate  conversion  from  tacrolimus  to cyclosporine in the treatment of posttransplantation diabetes mellitus. Transplant Proc. 2005;37:999-1000.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Charbit M, Blazy I, Pouzet B. et al. Nitric oxide and the renin angiotensin system: contribution to blood pressure in the young rat. Pediatr. Nephrol. 1997;11:617-622.</mixed-citation><mixed-citation xml:lang="en">Charbit M, Blazy I, Pouzet B. et al. Nitric oxide and the renin angiotensin system: contribution to blood pressure in the young rat. Pediatr. Nephrol. 1997;11:617-622.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cai Q, Mukku VK, Ahmad M. Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update. Current Cardiology Reviews. 2013;9:331-339.</mixed-citation><mixed-citation xml:lang="en">Cai Q, Mukku VK, Ahmad M. Coronary Artery Disease   in   Patients   with   Chronic   Kidney   Disease: A   Clinical    Update.    Current    Cardiology    Reviews. 2013;9:331-339.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rowland CM., Pullinger CR, Luke MM. Lipoprotein(a), LPA Ile4399Met, and fibrin clot properties. Thrombosis Research. 2014;133(5):863-867.</mixed-citation><mixed-citation xml:lang="en">Rowland CM., Pullinger CR, Luke MM. Lipoprotein(a),  LPA  Ile4399Met,  and  fibrin  clot properties. Thrombosis Research. 2014;133(5):863-867.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Nordestgaard BG, Chapman J, Ray K, Bore ´n J et al. for the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.</mixed-citation><mixed-citation xml:lang="en">Nordestgaard BG, Chapman J, Ray K, Bore ´n J et al. for the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
